#152

COMPLETE

Collector:	Web Link 1 (Web Link)
Started:	Tuesday, October 07, 2025 12:57:22 PM
Last Modified:	Tuesday, October 07, 2025 1:02:59 PM
Time Spent:	00:05:37
IP Address:	205.250.120.24

Page 2: Part 1

Q1

Title of activity

Climate-Conscious Asthma Management:Rethinking inhaler use in a changing environment

Q2

Date of activity

October 16, 2025

Q3

What is your role in the CPD activity? (Select all that apply)

Speaker

Q4

What's your practice type?

Combination - Community and Academic

Q5

Please indicate:

I HAVE a relationship with a for-profit and/or a not-for-profit organization to disclose.If so, please indicate below (questions 5 to 10) the organization(s) with which you have/had a relationship over the previous two years and briefly describe the nature of that relationship.

Q6

Any direct financial payments including receipt of honoraria

Name of FOR PROFIT and/or NOT-for-profit organization(s) (separate with commas)	**CASCADES stipend (Creating a Sustainable Canadian Health System in a Climate Crisis) a not-for-profit organization funded by Environment and Climate Change Canada,**
Description of relationship(s)	**stipend for work on the National Advisory Committee on Inhaler Sustainability and for my role as National Chair of Sustainable Prescribing and national innovation grant and support from the CASCADES Network for The Critical Project**

Q7

Membership on advisory boards or speakers' bureaus

Name of FOR PROFIT and/or NOT-for-profit organization(s) (separate with commas)	**BC Guidelines and Protocols Advisory Committee, Health Quality BC**
Description of relationship(s)	**Committee member for BC asthma and COPD guidelines, HQBC Low Carbon High Quality Care Advisory Board member**

Q8

Funded grants or clinical trials

Respondent skipped this question

Q9

Patents on a drug, product or device

Respondent skipped this question

Q10

All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity

Respondent skipped this question

Page 3: Part 2: To be completed by presenters only

Q11

I intend to use trade names during my presentation.Note: Only generic names should be used whenever possible. If trade names are used, they should be accompanied by the generic name.

No

Q12

I intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. “off-label” use of medication).Note: You must declare all off-label use to the audience during your presentation.

No

Q13

If you answered "Yes" to the previous question, are the medications recommended manufactured by companies you have received funding from?

N/A

Q14

I acknowledge that the National Standard requires that any description of therapeutic options utilize generic names (or both generic and trade names) and not reflect exclusivity and branding.

Yes

Page 4: Part 3 (Anonymous & Optional): Equity, Diversity and Inclusion (EDI)

Q15

I confirm that I've completed the EDI Survey linked above

Yes

Page 5: PART 4: Acknowledgement and signature (for all)

Q16

First Name:

Valeria

Q17

Last Name:

Stoynova

Q18

Gender Pronouns - How would you like us to address you?

She/Her

Q19

Please review and check the items below.

I confirm that the above information is accurate and complete.

,

I understand that this information may be publicly available